| pubmed-article:8828995 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8828995 | lifeskim:mentions | umls-concept:C0036668 | lld:lifeskim |
| pubmed-article:8828995 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:8828995 | lifeskim:mentions | umls-concept:C0392156 | lld:lifeskim |
| pubmed-article:8828995 | lifeskim:mentions | umls-concept:C0079809 | lld:lifeskim |
| pubmed-article:8828995 | lifeskim:mentions | umls-concept:C0439611 | lld:lifeskim |
| pubmed-article:8828995 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8828995 | pubmed:dateCreated | 1996-12-6 | lld:pubmed |
| pubmed-article:8828995 | pubmed:abstractText | Previous polysomnographic (PSG) investigations have reported a rhythmic electromyographic (EMG) pattern (0.5-3.0 cps) of leg movement activity in a subset of patients with neuroleptic-induced akathisia (NIA). It has been suggested that this EMG pattern may represent a pathophysiological correlate of NIA and thus have clinical utility as an objective marker for this condition. We present preliminary measures of sensitivity and specificity for this EMG pattern as a diagnostic marker for NIA for 26 neuroleptic-treated patients. The EMG marker yielded a diagnostic sensitivity of 68.9% and a specificity of 70.0%, falling just short of statistical significance (Fisher's exact test p = 0.06). Quantitative analysis of the EMG pattern revealed a significant positive correlation between the percentage of time the NIA marker occurred during wakefulness and corresponding chlorpromazine equivalent levels. Clinical demographic findings for true-positive, false-positive, true-negative, and false-negative groups are discussed. Overall findings suggest that this particular pattern of EMG marker activity observed in neuroleptic-treated patients during PSG and EMG studies is valuable in facilitating the diagnosis and monitoring treatment. | lld:pubmed |
| pubmed-article:8828995 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8828995 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8828995 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8828995 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8828995 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8828995 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8828995 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8828995 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8828995 | pubmed:issn | 0362-5664 | lld:pubmed |
| pubmed-article:8828995 | pubmed:author | pubmed-author:RichardsonG... | lld:pubmed |
| pubmed-article:8828995 | pubmed:author | pubmed-author:HungTT | lld:pubmed |
| pubmed-article:8828995 | pubmed:author | pubmed-author:LukasS ESE | lld:pubmed |
| pubmed-article:8828995 | pubmed:author | pubmed-author:WinkelmanJ... | lld:pubmed |
| pubmed-article:8828995 | pubmed:author | pubmed-author:CunninghamS... | lld:pubmed |
| pubmed-article:8828995 | pubmed:author | pubmed-author:DorseyC MCM | lld:pubmed |
| pubmed-article:8828995 | pubmed:author | pubmed-author:SholarM BMB | lld:pubmed |
| pubmed-article:8828995 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8828995 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:8828995 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8828995 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8828995 | pubmed:pagination | 321-32 | lld:pubmed |
| pubmed-article:8828995 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:meshHeading | pubmed-meshheading:8828995-... | lld:pubmed |
| pubmed-article:8828995 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8828995 | pubmed:articleTitle | An electromyographic marker for neuroleptic-induced akathisia: preliminary measures of sensitivity and specificity. | lld:pubmed |
| pubmed-article:8828995 | pubmed:affiliation | Sleep Disorders Center and Sleep Research Program, McLean Hospital, Belmont, USA. | lld:pubmed |
| pubmed-article:8828995 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8828995 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8828995 | lld:pubmed |
